Related Experiment Video

Updated: Sep 27, 2026

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Surrogate endpoints in cancer drug development

Karol Sikora1

  • 1Mereside, Alderley Park, Cheshire, UK SK10 4TG. karol.sikora@astrazeneca.com

Drug Discovery Today
|January 28, 2003
PubMed

Insights

Numerous novel cancer drugs targeting specific mechanisms are entering clinical trials. Innovative development methods and efficacy biomarkers are crucial for success, requiring academic-industry collaboration.

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Discovery

Background:

  • Significant advancements in cancer molecular biology have identified numerous validated drug targets.
  • A substantial number of novel, mechanistically targeted anticancer agents are progressing towards clinical trials.

Purpose of the Study:

  • To highlight the need for innovative clinical development strategies for emerging cancer therapies.
  • To emphasize the importance of discovering novel efficacy biomarkers in cancer drug development.

Main Methods:

  • Review of current trends in cancer drug discovery and development.
  • Discussion of preclinical screening and pharmaceutical formulation of targeted agents.
  • Exploration of novel clinical trial designs for dose determination and scheduling.

Main Results:

  • Anticipation of a large influx of targeted cancer drugs into clinical trials within three years.
  • Identification of the necessity for advanced methods in clinical development and efficacy assessment.
  • Recognition of the critical role of academic-pharmaceutical partnerships.

Conclusions:

  • The rapid advancement of cancer molecular biology necessitates innovative approaches to drug development.
  • Effective clinical translation of novel targeted cancer therapies requires optimized trial designs and surrogate efficacy markers.
  • Strong collaborations between academic institutions and the pharmaceutical industry are vital for accelerating progress in cancer treatment.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...